NCT05289687 2026-03-02
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
Eastern Cooperative Oncology Group
Phase 2 Recruiting
Clinical Trials
1 trialsRecruiting × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × Hyaluronoglucosaminidase × Clear all